Niacin for lipid disorders

References

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269(23): 3015–23
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Conference Summary. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993; 269(4): 505–10
   PubMed Web of Science ®Google Scholar
• Gerace TA, Hollis J, Ockene JK, et al. Smoking cessation and change in diastolic blood pressure, body weight, and plasma lipids. MR-FIT Research Group. Prev Med 1991; 20(5): 602–20
   PubMed Web of Science ®Google Scholar
• Grundy SM. Adherence to cholesterol-lowering diets. (Editorial) Arch Intern Med 1992; 152(6): 1139
   PubMedGoogle Scholar
• Henkin Y, Garber DW, Osterlund LC, et al. Saturated fats, cholesterol, and dietary compliance. Arch Intern Med 1992; 152(6): 1167–74
   PubMedGoogle Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351–64
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251(3): 365–74
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317(20): 1237–45
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–9
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79(1): 8–15
   PubMed Web of Science ®Google Scholar
• King JM, Crouse JR, Terry JG, et al. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 1994; 97(4): 323–31
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323(19): 1289–98
   PubMed Web of Science ®Google Scholar
• Blankellhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257 (23): 3233–40 [Erratum, JAMA 1988; 259(18): 2698]
   PubMed Web of Science ®Google Scholar
• Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264(23): 3007–12
   PubMed Web of Science ®Google Scholar
• Berge KG, Achor RW, Christensen NA, et al. Hypercholesteremia and nicotinic acid: a long term study. Am J Med 1961; 31: 24–36
   Web of Science ®Google Scholar
• McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271(9): 672–7
   PubMed Web of Science ®Google Scholar
• Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226(4): 271–6
   PubMed Web of Science ®Google Scholar
• Gurakar A, Hoeg JM, Kostner G, et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57(2–3): 293–301
   PubMed Web of Science ®Google Scholar
• Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp (a) levels: opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992; 89(4): 1166–71
   PubMed Web of Science ®Google Scholar
• Keenan JM, Fontaine PL, Wenz JB, et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991; 151(7): 1424–32
   PubMedGoogle Scholar
• Squires RW, Allison TG, Gau GT, et al. Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol. Mayo Clin Proc 1992; 67(9): 855–60
   PubMed Web of Science ®Google Scholar
• Alderman JD, Pasternak RC, Sacks FM, et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989; 64(12): 725–9
   PubMed Web of Science ®Google Scholar
• Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 1988; 148(11): 2493–5
   PubMedGoogle Scholar
• Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with isolated very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992; 69(12): 1083–5
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231(4): 360–81
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 Dec; 8(6): 1245–55
   PubMed Web of Science ®Google Scholar
• Malloy MJ, Kane JP, Kunitake ST, et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987; 107(5): 616–23
   PubMed Web of Science ®Google Scholar
• Christensen NA, Achor RW, Berge KG, et al. Nicotinic acid treatment of hypercholesteremia: comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961; 177: 546–50
   PubMed Web of Science ®Google Scholar
• Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyper-lipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34(7): 642–50
   PubMed Web of Science ®Google Scholar
• Gray DR, Morgan T, Chretien SD, et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994; 121(4): 252–8
   PubMed Web of Science ®Google Scholar
• Brown WV, Howard WJ, Field L. Nicotinic acid and its derivatives. In: Rifkind BM, ed. Drag treatment of hyperlipidemia. New York: Dekker, 1990: 189–213
   Google Scholar
• Bays HE, Dujovne CA. Drug therapy for hyperlipidemia: when reducing cardiovascular risk is a priority. Postgrad Med 1992; 91 (5): 162–72 [Erratum, Postgrad Med 1992; 91(8): 76]
   PubMed Web of Science ®Google Scholar
• Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc 1991; 66(1): 23–8
   PubMed Web of Science ®Google Scholar
• Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92(1): 77–81
   PubMed Web of Science ®Google Scholar
• McEvoy GK, ed. Niacin. AHFS drug information 92. Bethesda: American Society of Hospital Pharmacists, 1992: 961–4
   Google Scholar
• Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264(23): 3025–33
   PubMed Web of Science ®Google Scholar